Seeking Alpha

InterMune (ITMN) +5.7% AH after announcing Canada's national health service has approved its...

InterMune (ITMN) +5.7% AH after announcing Canada's national health service has approved its Esbriet pulmonary fibrosis drug - the company expects sales to begin on Jan. 1. Esbriet has already been approved for use in Japan, South Korea, and 29 European countries, but FDA approval is still pending the outcome of clinical trials. (previous)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs